ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
Protocol ID
I3Y-MC-JPEH
Condition/s
Glioma
Diagnosis Stage
Newly diagnosed
Location
QLD, WA
Sponsor
ICON
Links
External Registry ≫
Trial Status
Open
Sites
Perth Children's Hospital
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
Up to 20 Years
International registry ID's
NCT06413706
Back to Registry
Study Title Randomized Open-Label Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
Protocol ID I3Y-MC-JPEH
Disease (Sub Disease) Glioma
Diagnosis Stage Newly diagnosed
Location QLD / WA
Sponsor ICON/
Links https://clinicaltrials.gov/study/NCT06413706
Trial Status Open
Sites Perth Children's Hospital/ Queensland Children's Hospital/
Study Type Treatment
Phase Phase 2
Age Eligibility Up to 20 Years
International registry ID's NCT06413706

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.